ArticleFrontiers in psychiatry2021
The Need for Psychedelic-Assisted Therapy in the Black Community and the Burdens of Its Provision.
Article in Frontiers in psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- A systematic review of participant diversity in psychedelic-assisted psychotherapy trials.Psychiatry research · 2025Pooled it
- Chaplains in Psychedelic Assisted Therapy: Rationale and Competencies.Journal of religion and health · 2026Article
- Ethical issues with psychedelic-assisted treatments in psychiatry: A systematic scoping review.Psychological medicine · 2025Article
- Key Features of Culturally Inclusive, -Affirming and Contextually Relevant Mental Health Care and Healing Practices with Black Canadians: A Scoping Review.International journal of environmental research and public health · 2025Article
- Quantitative and qualitative influences of spiritual connection and natural imagery on perception of art in clinical psychedelic dosing settings.Scientific reports · 2025Article
- History, Hype, and Responsible Psychedelic Medicine: A Qualitative Study of Psychedelic Researchers.Journal of bioethical inquiry · 2025Article
- Minorities' Diminished Psychedelic Returns: Income and Educations Impact on Whites, Blacks, Hispanics, and Asians.Journal of racial and ethnic health disparities · 2025Article
- The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.Therapeutic advances in psychopharmacology · 2025Article
- Ethnoracial inclusion in clinical trials of psychedelics: a systematic review.EClinicalMedicine · 2024Review
- Ensuring psychedelic treatments and research do not leave anyone behind.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Perceptions of psychedelic-assisted therapy among Black Americans.Journal of mood and anxiety disorders · 2023Article
- Perceived risk of LSD varies with age and race: evidence from 2019 United States cross-sectional data.Social psychiatry and psychiatric epidemiology · 2023Article
- Investigating the associations of acute psychedelic experiences and changes in racial trauma symptoms, psychological flexibility, and substance use among People with Racial and Ethnic Minoritized Identities in the United States and Canada.Journal of substance use and addiction treatment · 2023Article
- Perspectives on the therapeutic potential of MDMA: A nation-wide exploratory survey among substance users.Frontiers in psychiatry · 2023Article
- The illusion of inclusion: contextual behavioral science and the Black community.Frontiers in psychology · 2023Review
- Racism and censorship in the editorial and peer review process.Frontiers in psychology · 2023Review
- Race and ethnicity moderate the associations between lifetime psilocybin use and crime arrests.Frontiers in psychiatry · 2023Article
- Psychedelic Microdosing among Young Adults from Southern California.Journal of psychoactive drugsArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psychedelic medicine is an emerging field that examines entheogens, psychoactive substances that produce non-ordinary states of consciousness (NOSC). 3,4-methylenedioxymethamphetamine (MDMA) is currently in phase-3 FDA clinical trials in the United States (US) and Canada to treat the symptoms of posttraumatic stress disorder (PTSD). MDMA is used in conjunction with manualized therapy, because of its effectiveness in reducing fear-driven stimuli that contribute to trauma and anxiety symptoms. In 2017, the FDA designated MDMA as a "breakthrough therapy," signaling that it has advantages in safety, efficacy, and compliance over available medication for the treatment of trauma-, stress-, and anxiety-related disorders such as PTSD. In the US and Canada, historical and contemporary racial mistreatment is frequently experienced by Black people via a variety of macro and micro insults. Such experiences trigger physiological responses of anxiety and fear, which are associated with chronically elevated stress hormone levels (e.g., cortisol and epinephrine), similar to levels documented among those diagnosed with an anxiety disorder. This paper will explore the benefits of entheogens within psychedelic assisted-therapy and their potential benefits in addressing the sequelae of pervasive and frequent negative race-based experiences and promoting healing and thriving among Black, Indigenous and other People of Color (BIPOC). The author(s) discuss the ethical responsibility for providing psychedelic-assisted therapy within a culturally competent provider framework and the importance of psychedelic researchers to recruit and retain BIPOC populations in research and clinical training.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.